Movement Alert｜Hengrui Medicine Rises 3.01% in Regular Trading, Class 1 Innovative Drug Luzunore Sodium Tablets Approved for Market

Market Focus05-29

On May 29, Hengrui Medicine rose 3.01% in regular trading, trading at HKD 59.85 per share, with trading volume of HKD 204 million.

On the news front, the company announced on May 28 that its self-developed Class 1 innovative drug Luzunore Sodium Tablets (SHR4640) received approval from China's National Medical Products Administration. The product is China's first domestically developed next-generation highly selective URAT1 inhibitor, indicated for gout patients with hyperuricemia.

The market opportunity is substantial. China has approximately 180 million hyperuricemia patients and around 36 million gout patients, representing strong chronic disease demand. The competitive landscape is favorable — globally, only one similar drug (Dotinurad) is currently on the market, with global sales of approximately USD 39.34 million, leaving significant room for Hengrui to capture market share. Additionally, the company received clinical trial approval for SHR-1819 injection targeting pediatric atopic dermatitis and HRS-1635 tablets for B-cell malignancies, further enriching its innovation pipeline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126255650?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 11:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126255650","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Hengrui Medicine Rises 3.01% in Regular Trading, Class 1 Innovative Drug Luzunore Sodium Tablets Approved for Market","media":"Market Focus","content":"<p><p>On May 29, Hengrui Medicine rose 3.01% in regular trading, trading at HKD 59.85 per share, with trading volume of HKD 204 million.</p><p>On the news front, the company announced on May 28 that its self-developed Class 1 innovative drug Luzunore Sodium Tablets (SHR4640) received approval from China's National Medical Products Administration. The product is China's first domestically developed next-generation highly selective URAT1 inhibitor, indicated for gout patients with hyperuricemia.</p><p>The market opportunity is substantial. China has approximately 180 million hyperuricemia patients and around 36 million gout patients, representing strong chronic disease demand. The competitive landscape is favorable — globally, only one similar drug (Dotinurad) is currently on the market, with global sales of approximately USD 39.34 million, leaving significant room for Hengrui to capture market share. Additionally, the company received clinical trial approval for SHR-1819 injection targeting pediatric atopic dermatitis and HRS-1635 tablets for B-cell malignancies, further enriching its innovation pipeline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hengrui Medicine Rises 3.01% in Regular Trading, Class 1 Innovative Drug Luzunore Sodium Tablets Approved for Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hengrui Medicine Rises 3.01% in Regular Trading, Class 1 Innovative Drug Luzunore Sodium Tablets Approved for Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-29 11:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 29, Hengrui Medicine rose 3.01% in regular trading, trading at HKD 59.85 per share, with trading volume of HKD 204 million.</p><p>On the news front, the company announced on May 28 that its self-developed Class 1 innovative drug Luzunore Sodium Tablets (SHR4640) received approval from China's National Medical Products Administration. The product is China's first domestically developed next-generation highly selective URAT1 inhibitor, indicated for gout patients with hyperuricemia.</p><p>The market opportunity is substantial. China has approximately 180 million hyperuricemia patients and around 36 million gout patients, representing strong chronic disease demand. The competitive landscape is favorable — globally, only one similar drug (Dotinurad) is currently on the market, with global sales of approximately USD 39.34 million, leaving significant room for Hengrui to capture market share. Additionally, the company received clinical trial approval for SHR-1819 injection targeting pediatric atopic dermatitis and HRS-1635 tablets for B-cell malignancies, further enriching its innovation pipeline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1126255650","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126255650","pubTimestamp":1780027083,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 29, Hengrui Medicine rose 3.01% in regular trading, trading at HKD 59.85 per share, with trading volume of HKD 204 million.On the news front, the company announced on May 28 that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"动静快讯|恒瑞医药常规交易涨3.01%1类创新药芦珠诺钠片获批上市","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"On May 29, Hengrui Medicine rose 3.01% in regular trading, trading at HKD 59.85 per share, with trading volume of HKD 204 million.On the news front, the company announced on May 28 that its self-developed Class 1 innovative drug Luzunore Sodium Tablets (SHR4640) received approval from China's National Medical Products Administration. The product is China's first domestically developed next-generation highly selective URAT1 inhibitor, indicated for gout patients with hyperuricemia.The market opportunity is substantial. China has approximately 180 million hyperuricemia patients and around 36 million gout patients, representing strong chronic disease demand. The competitive landscape is favorable — globally, only one similar drug (Dotinurad) is currently on the market, with global sales of approximately USD 39.34 million, leaving significant room for Hengrui to capture market share. Additionally, the company received clinical trial approval for SHR-1819 injection targeting pediatric atopic dermatitis and HRS-1635 tablets for B-cell malignancies, further enriching its innovation pipeline.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126255650","isCrawlerRequest":true}